脓毒症免疫失衡机制及中医治疗(4)
[2]Lagu T，Rothberg MB，Shieh MS，et al.Hospitalizations，costs，and outcomes of severe sepsis in the United States 2003 to 2007[J].Crit Care Med，2012，40(3)：754-761.
[3]于洋，袁光雄.脓毒症流行病学的研究进展[J].临床急诊杂志，2015，16(6)：416-418，420.
[4]张庆红，姚咏明.严重脓毒症与免疫功能障碍[J].医学与哲学，2014，35(2)：18-22，27.
[5]饶小龙，孙航，吴传新.HMGB1在脓毒症中的致病机制及靶向治疗前景[J].生理科学进展，2014，45(6)：458-461.
[6]Lee SA，Kwak MS，Kim S，et al.The role of high mobility group box 1 in innate immunity[J].Yonsei Med J，2014，55(5)：1165-1176.
, 百拇医药
[7]Chen Y，Huang XJ，Yu N，et al.HMGB1 Contributes to the Expression of P-Glycoprotein in Mouse Epileptic Brain through Toll-Like Receptor 4 and Receptor for Advanced Glycation End Products[J].PLoS One，2015，10(10)：e0140918.
[8]Nogueira-Machado JA，Volpe CM，Veloso CA，et al.HMGB1，TLR and RAGE：a functional tripod that leads to diabetic inflammation[J].Expert Opin Ther Targets，2011，15(8)：1023-1035.
[9]Chirico V，Lacquaniti A，Salpietro V，et al.High-mobility group box 1(HMGB1)in childhood：from bench to bedside[J].Eur J Pediatr，2014，173(9)：1123-1136.
, 百拇医药
[10]Takeda K，Akira S.Toll-like receptors in innate immunity[J].Int Immunol，2005，17(1)：1-14.
[11]劉雪燕，徐勇.Toll样受体4与脓毒症相关性的研究进展[J].中国生物制品学杂志，2012，25(12)：1723-1728.
[12]Lima CX，Souza DG，Amaral FA，et al.Therapeutic Effects of Treatment with Anti-TLR2 and Anti-TLR4 Monoclonal Antibodies in Polymicrobial Sepsis[J].PLoS One，2015，10(7)：e0132336.
[13]Chen GY，Brown NK，Zheng P，et al.Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity[J].Glycobiology，2014，24(9)：800-806.
, 百拇医药
[14]Chen GY，Tang J，Zheng P，et al.CD24 and Siglec-10 selectively repress tissue damage-induced immune responses[J].Science，2009，323(5922)：1722-1725.
[15]Chen GY，Chen X，King S，et al.Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-Siglec G interaction[J].Nat Biotechnol，2011，29(5)：428-435.
[16]Rauvala H，Rouhiainen A.RAGE as a receptor of HMGB1(Amphoterin)：roles in health and disease[J].Curr Mol Med，2007，7(8)：725-734.
, 百拇医药
[17]Tsung A，Tohme S，Billiar TR.High-mobility group box-1 in sterile inflammation[J].J Intern Med，2014，276(5)：425-443.
[18]Tieu R，Amancha PK，Villinger F，et al.TIM-3，a Possible Target for Immunotherapy in Cancer and Chronic Viral Infections[J].Austin Virol Retro Virol，2014，1(2).pii：6.Epub 2014 Dec 5.
[19]Chiba S，Baghdadi M，Akiba H，et al.Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1[J].Nat Immunol，2012，13(9)：832-842., http://www.100md.com(卢幼然狄浩然丁军颖郭玉红刘清泉)
[3]于洋，袁光雄.脓毒症流行病学的研究进展[J].临床急诊杂志，2015，16(6)：416-418，420.
[4]张庆红，姚咏明.严重脓毒症与免疫功能障碍[J].医学与哲学，2014，35(2)：18-22，27.
[5]饶小龙，孙航，吴传新.HMGB1在脓毒症中的致病机制及靶向治疗前景[J].生理科学进展，2014，45(6)：458-461.
[6]Lee SA，Kwak MS，Kim S，et al.The role of high mobility group box 1 in innate immunity[J].Yonsei Med J，2014，55(5)：1165-1176.
, 百拇医药
[7]Chen Y，Huang XJ，Yu N，et al.HMGB1 Contributes to the Expression of P-Glycoprotein in Mouse Epileptic Brain through Toll-Like Receptor 4 and Receptor for Advanced Glycation End Products[J].PLoS One，2015，10(10)：e0140918.
[8]Nogueira-Machado JA，Volpe CM，Veloso CA，et al.HMGB1，TLR and RAGE：a functional tripod that leads to diabetic inflammation[J].Expert Opin Ther Targets，2011，15(8)：1023-1035.
[9]Chirico V，Lacquaniti A，Salpietro V，et al.High-mobility group box 1(HMGB1)in childhood：from bench to bedside[J].Eur J Pediatr，2014，173(9)：1123-1136.
, 百拇医药
[10]Takeda K，Akira S.Toll-like receptors in innate immunity[J].Int Immunol，2005，17(1)：1-14.
[11]劉雪燕，徐勇.Toll样受体4与脓毒症相关性的研究进展[J].中国生物制品学杂志，2012，25(12)：1723-1728.
[12]Lima CX，Souza DG，Amaral FA，et al.Therapeutic Effects of Treatment with Anti-TLR2 and Anti-TLR4 Monoclonal Antibodies in Polymicrobial Sepsis[J].PLoS One，2015，10(7)：e0132336.
[13]Chen GY，Brown NK，Zheng P，et al.Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity[J].Glycobiology，2014，24(9)：800-806.
, 百拇医药
[14]Chen GY，Tang J，Zheng P，et al.CD24 and Siglec-10 selectively repress tissue damage-induced immune responses[J].Science，2009，323(5922)：1722-1725.
[15]Chen GY，Chen X，King S，et al.Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-Siglec G interaction[J].Nat Biotechnol，2011，29(5)：428-435.
[16]Rauvala H，Rouhiainen A.RAGE as a receptor of HMGB1(Amphoterin)：roles in health and disease[J].Curr Mol Med，2007，7(8)：725-734.
, 百拇医药
[17]Tsung A，Tohme S，Billiar TR.High-mobility group box-1 in sterile inflammation[J].J Intern Med，2014，276(5)：425-443.
[18]Tieu R，Amancha PK，Villinger F，et al.TIM-3，a Possible Target for Immunotherapy in Cancer and Chronic Viral Infections[J].Austin Virol Retro Virol，2014，1(2).pii：6.Epub 2014 Dec 5.
[19]Chiba S，Baghdadi M，Akiba H，et al.Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1[J].Nat Immunol，2012，13(9)：832-842., http://www.100md.com(卢幼然狄浩然丁军颖郭玉红刘清泉)